Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fffda8b59ac378c0e7cd94cdf51bbfd7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9fb7bbc09927d64558e1e99a3b7c719b |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 |
filingDate |
2017-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c1afc28128d65f67e7644d949ec165f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2339a2bbe3d83c781c12a0f09bdf3fd |
publicationDate |
2019-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2019091330-A1 |
titleOfInvention |
Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites |
abstract |
The present disclosure is directed to formulations and methods for treatment of disease such as chemoprevention of cancer, for example oral squamous cell carcinoma (OSCC), and for methods of preparing the formulations. Further, the disclosure relates to local administration in slow release dosage forms for treatment of disease. The extended-release formulations are comprised of biodegradable polymeric implants (for example millicylinders and microspheres as well as in situ forming gels) and therapeutic agents selected from an anti-interleukin 6 agent, a synthetic vitamin A analogue and/or metabolite, and/or an estradiol metabolite for the local delivery of therapeutic agents to a site where a cancer has been previously excised or to prevent progression of a precancerous lesion. |
priorityDate |
2016-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |